CIK 0001321834
- Non-accelerated filer
- Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- 4 Grant or award VP - Finance, Treasurer acquired 36,277 shares (grant or award)
- 4 Gift Chief Executive Officer gave 150,000 shares (gift)
- 5 Insider Annual Insider Trading Report
- 4 Gift Chief Executive Officer gave 27,500 shares (gift)
- 4 Open-market buy Chief Executive Officer bought 2,500 shares at an average $2.23 ($5,567)
- 4 Open-market buy Executive Chairman, Secretary bought 2,100 shares at $1.34 ($2,814)
- 4/A Grant or award Director acquired 50,000 shares (grant or award)
- 4 Grant or award Director acquired 70,000 shares (grant or award)
- 4 Grant or award Director acquired 55,000 shares (grant or award)
- 4 Grant or award VP - Finance, Treasurer acquired 22,500 shares (grant or award)
- 4 Grant or award Director acquired 48,125 shares (grant or award)
- 4 Grant or award Director acquired 32,083 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy VP - Finance, Treasurer bought 3,500 shares at $1.50 ($5,250)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Executive Chairman, Secretary acquired 70,000 shares (grant or award)
- 4 Grant or award Director acquired 50,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
Page 6 of 7 · 132 filings